These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 23639651)

  • 41. [Design, synthesis and biological assay of novel tripeptidic tetrazoles as inhibitors of 20S proteasome].
    Ma YH; Xu B; Cui JR; Yang ZJ; Zhang LR; Zhang LH
    Yao Xue Xue Bao; 2012 Apr; 47(4):472-8. PubMed ID: 22799029
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A novel tamoxifen derivative, ridaifen-F, is a nonpeptidic small-molecule proteasome inhibitor.
    Hasegawa M; Yasuda Y; Tanaka M; Nakata K; Umeda E; Wang Y; Watanabe C; Uetake S; Kunoh T; Shionyu M; Sasaki R; Shiina I; Mizukami T
    Eur J Med Chem; 2014 Jan; 71():290-305. PubMed ID: 24321833
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Discovery and development of second-generation proteasome inhibitors.
    Kirk CJ
    Semin Hematol; 2012 Jul; 49(3):207-14. PubMed ID: 22726543
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Phenoxypropanolamine derivatives as selective inhibitors of the 20S proteasome β1 and β5 subunits.
    Hovhannisyan AA; Pham TH; Bouvier D; Tan X; Touhar S; Mkryan GG; Dallakyan AM; El Amri C; Melikyan GS; Reboud-Ravaux M; Bouvier-Durand M
    Bioorg Med Chem Lett; 2017 Dec; 27(23):5172-5178. PubMed ID: 29113763
    [TBL] [Abstract][Full Text] [Related]  

  • 45. C1 and N5 derivatives of cerpegin: synthesis of a new series based on structure-activity relationships to optimize their inhibitory effect on 20S proteasome.
    Hovhannisyan A; Pham TH; Bouvier D; Qin L; Melikyan G; Reboud-Ravaux M; Bouvier-Durand M
    Bioorg Med Chem Lett; 2013 May; 23(9):2696-703. PubMed ID: 23541650
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Design, synthesis and biological evaluation of dipeptides as novel non-covalent 20S proteasome inhibitors.
    Yang YJ; Wang K; Yang Y; Lai FF; Chen XG; Xiao ZY
    J Asian Nat Prod Res; 2021 May; 23(5):436-451. PubMed ID: 33844614
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Design of proteasome inhibitors with oral efficacy in vivo against
    Xie SC; Metcalfe RD; Mizutani H; Puhalovich T; Hanssen E; Morton CJ; Du Y; Dogovski C; Huang SC; Ciavarri J; Hales P; Griffin RJ; Cohen LH; Chuang BC; Wittlin S; Deni I; Yeo T; Ward KE; Barry DC; Liu B; Gillett DL; Crespo-Fernandez BF; Ottilie S; Mittal N; Churchyard A; Ferguson D; Aguiar ACC; Guido RVC; Baum J; Hanson KK; Winzeler EA; Gamo FJ; Fidock DA; Baud D; Parker MW; Brand S; Dick LR; Griffin MDW; Gould AE; Tilley L
    Proc Natl Acad Sci U S A; 2021 Sep; 118(39):. PubMed ID: 34548400
    [TBL] [Abstract][Full Text] [Related]  

  • 48. 20S proteasome as novel biological target for organochalcogenanes.
    Piovan L; Milani P; Silva MS; Moraes PG; Demasi M; Andrade LH
    Eur J Med Chem; 2014 Feb; 73():280-5. PubMed ID: 24463395
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Design, synthesis, and biological evaluation of novel phenol ether derivatives as non-covalent proteasome inhibitors.
    Yu J; Xu L; Hong D; Zhang X; Liu J; Li D; Li J; Zhou Y; Liu T
    Eur J Med Chem; 2019 Jan; 161():543-558. PubMed ID: 30391816
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S beta5-subunit.
    Blackburn C; Gigstad KM; Hales P; Garcia K; Jones M; Bruzzese FJ; Barrett C; Liu JX; Soucy TA; Sappal DS; Bump N; Olhava EJ; Fleming P; Dick LR; Tsu C; Sintchak MD; Blank JL
    Biochem J; 2010 Sep; 430(3):461-76. PubMed ID: 20632995
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Optimization of subsite binding to the beta5 subunit of the human 20S proteasome using vinyl sulfones and 2-keto-1,3,4-oxadiazoles: syntheses and cellular properties of potent, selective proteasome inhibitors.
    Rydzewski RM; Burrill L; Mendonca R; Palmer JT; Rice M; Tahilramani R; Bass KE; Leung L; Gjerstad E; Janc JW; Pan L
    J Med Chem; 2006 May; 49(10):2953-68. PubMed ID: 16686537
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Activation of Chymotrypsin-Like Activity of the Proteasome during Ischemia Induces Myocardial Dysfunction and Death.
    Sanchez G; Berrios D; Olmedo I; Pezoa J; Riquelme JA; Montecinos L; Pedrozo Z; Donoso P
    PLoS One; 2016; 11(8):e0161068. PubMed ID: 27529620
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Computational inhibition studies of the human proteasome by argyrin-based analogues with subunit specificity.
    Loizidou EZ; Zeinalipour-Yazdi CD
    Chem Biol Drug Des; 2014 Jul; 84(1):99-107. PubMed ID: 24521156
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immunoproteasome-selective inhibitors: An overview of recent developments as potential drugs for hematologic malignancies and autoimmune diseases.
    Xi J; Zhuang R; Kong L; He R; Zhu H; Zhang J
    Eur J Med Chem; 2019 Nov; 182():111646. PubMed ID: 31521028
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Synthesis and biological evaluation of boron peptide analogues of Belactosin C as proteasome inhibitors.
    Nakamura H; Watanabe M; Ban HS; Nabeyama W; Asai A
    Bioorg Med Chem Lett; 2009 Jun; 19(12):3220-4. PubMed ID: 19428245
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Molecular modeling on porphyrin derivatives as β5 subunit inhibitor of 20S proteasome.
    Arba M; Nur-Hidayat A; Ruslin ; Yusuf M; Sumarlin ; Hertadi R; Wahyudi ST; Surantaadmaja SI; Tjahjono DH
    Comput Biol Chem; 2018 Jun; 74():230-238. PubMed ID: 29674291
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Structure-Based Optimization and Discovery of M3258, a Specific Inhibitor of the Immunoproteasome Subunit LMP7 (β5i).
    Klein M; Busch M; Friese-Hamim M; Crosignani S; Fuchss T; Musil D; Rohdich F; Sanderson MP; Seenisamy J; Walter-Bausch G; Zanelli U; Hewitt P; Esdar C; Schadt O
    J Med Chem; 2021 Jul; 64(14):10230-10245. PubMed ID: 34228444
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Design, synthesis, and biological evaluation of some novel naphthoquinone-glycine/β-alanine anilide derivatives as noncovalent proteasome inhibitors.
    Tatar I; Uysal S; Yilmaz S; Tarikogullari AH; Ballar Kirmizibayrak P; Soyer Z
    Chem Biol Drug Des; 2023 Jun; 101(6):1283-1298. PubMed ID: 36762979
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Diabetogenic agent alloxan is a proteasome inhibitor.
    Zhou W; Wei L; Xiao T; Lai C; Peng M; Xu L; Luo X; Deng S; Zhang F
    Biochem Biophys Res Commun; 2017 Jun; 488(2):400-406. PubMed ID: 28502636
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Proteasome inhibitors.
    Cvek B
    Prog Mol Biol Transl Sci; 2012; 109():161-226. PubMed ID: 22727422
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.